| __timestamp | Blueprint Medicines Corporation | Grifols, S.A. |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 660772000 |
| Thursday, January 1, 2015 | 14456000 | 736435000 |
| Friday, January 1, 2016 | 19218000 | 775266000 |
| Sunday, January 1, 2017 | 27986000 | 860348000 |
| Monday, January 1, 2018 | 47928000 | 814775000 |
| Tuesday, January 1, 2019 | 96388000 | 942821000 |
| Wednesday, January 1, 2020 | 157743000 | 985616000 |
| Friday, January 1, 2021 | 195293000 | 1061508000 |
| Saturday, January 1, 2022 | 237374000 | 1190423000 |
| Sunday, January 1, 2023 | 295141000 | 1254234000 |
| Monday, January 1, 2024 | 359272000 |
Unleashing the power of data
In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. From 2014 to 2023, Blueprint Medicines Corporation and Grifols, S.A. have shown contrasting approaches. Blueprint Medicines, a biopharmaceutical company, has seen its SG&A expenses grow from approximately $7.9 million in 2014 to nearly $295 million in 2023, marking a staggering increase of over 3,600%. This reflects its aggressive expansion and investment in growth.
Conversely, Grifols, a global healthcare company, maintained a more stable SG&A trajectory, with expenses rising from about $661 million in 2014 to $1.25 billion in 2023, a more modest 89% increase. This stability suggests a focus on efficiency and cost control.
Understanding these trends provides valuable insights into each company's strategic priorities and operational efficiencies, offering a window into their financial health and market strategies.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
AstraZeneca PLC and Grifols, S.A.: SG&A Spending Patterns Compared
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Blueprint Medicines Corporation Trends and Insights
SG&A Efficiency Analysis: Comparing Bio-Techne Corporation and Grifols, S.A.
Blueprint Medicines Corporation or Grifols, S.A.: Who Invests More in Innovation?
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ACADIA Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and PTC Therapeutics, Inc.
Blueprint Medicines Corporation and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Blueprint Medicines Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Axsome Therapeutics, Inc.
Breaking Down SG&A Expenses: Grifols, S.A. vs Amphastar Pharmaceuticals, Inc.